Theramir Ltd receives Impact award in Deloitte's Technology Fast 50 Program

14:18 - 15 May 2023

Companies

Theramir Ltd, a leading Cyprus-based biotechnology start-up specialising in innovative cancer therapeutics and diagnostics, has been presented with the prestigious Impact award in Deloitte's Middle East & Cyprus Technology Fast 50 program.

This recognition highlights Theramir's work in developing groundbreaking targeted cancer therapeutics and diagnostics.

The Technology Fast 50 program by Deloitte annually identifies and celebrates the 50 fastest-growing technology companies in the Middle East and Cyprus. Theramir's commitment to innovation and its remarkable contributions to the field of cancer research have earned the company this distinguished accolade.

Theramir Ltd is at the forefront of the biotechnology industry, pioneering the development of novel microRNA-based therapeutics and companion diagnostics. These cutting-edge technologies hold tremendous promise in revolutionising cancer treatment and improving patient outcomes.

"We are incredibly proud to receive this prestigious recognition," stated Dr. Marianna Prokopi-Demetriades, Co-founder of Theramir Ltd. "It serves as a testament to the unwavering dedication and hard work of our exceptional team. Our proprietary technologies showcase the immense potential of biotech companies to make a positive impact in the world. We remain fully committed to advancing their development and ensuring they reach those who need them most."

Theramir Ltd's commitment to innovation and its relentless pursuit of groundbreaking cancer therapeutics and diagnostics highlight the company's dedication to creating a lasting and meaningful impact on the lives of patients and healthcare providers alike.

Theramir Ltd receives Impact award in Deloitte's Technology Fast 50 Program

News Feed

Read More